65,437 trials
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
Obsessive Compulsive Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale — 2 participants
Hypertension · Left Ventricular Hypertrophy
Primary: Percent Change of B Type Natriuretic Peptides (BNP) Level — -29.2 Percent Change
Periodontal Disease
Primary: HbA1c Levels in Blood — 9.47; 10.27 Percentage — p=0.05
Neuromuscular Blockade
Primary: Number of Participants With Train-of-four (TOF) Ratio <0.9 at PACU Arrival — 91 participants
Iron Deficiency Anemia
Primary: Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize — 2 weeks
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants
Melanoma · Skin Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 18.8 Percentage of participants
Psoriasis
Primary: Participant Satisfaction With Injection Device Evaluated at Week 12 for Modified Intent-to-treat (mITT) Population — 8.9; 7.6 units on a scale — p=<0.001
Diabetes Mellitus, Type 2
Primary: Peak Oxygen Uptake (VO2) — 26.1; 27.6 ml O2 uptake/kg fat-free mass/minute — p=0.26
Smoking Cessation · Insurance Coverage
Primary: Percentage of Participants With 7-Day Point Prevalence (PP) of Abstinence — 20.8; 13.9 Percentage of Participants — p=0.0007
Carcinoma, Non-Small Cell Lung
Primary: Progression-Free Survival (PFS) — 8.0; 8.1; 7.1 months — p=0.3037
Islet Cell Carcinoma · Neuroendocrine Carcinoma · Neuroendocrine Tumor
Primary: Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on…
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose) — 6; 1…
Pediculus Humanus Capitis (Head Lice)
Primary: Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 56; 50…